Company intelligence / Profile preview
NovaDel Pharma
Bridgewater, New Jersey, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
NovaDel developed and commercialized FDA-approved oral spray versions of nitroglycerin (NitroMist) for angina and zolpidem (Zolpimist) for insomnia; Duromist (sildenafil oral spray) and other candidates for nausea, migraine, and CNS disorders were in earlier stages. Financial and strategic difficulties led to a halt/closure of operations around 2012, with bankruptcy threatened if no acquisition or financing was completed. Current activity is negligible or ceased.[1][3][5]
- Therapeutic areas
- CardiovascularGastroenterologyNeurologyMen's HealthPsychiatry
- Modalities
- Small moleculeDeviceHydrogel-based drug delivery therapy
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on NovaDel Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on NovaDel Pharma.